GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (NAS:ZVRA) » Definitions » Degree of Financial Leverage

ZVRA (Zevra Therapeutics) Degree of Financial Leverage : 0.73 (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Zevra Therapeutics's Degree of Financial Leverage for the quarter that ended in Sep. 2024 was 0.73. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Zevra Therapeutics's Degree of Financial Leverage or its related term are showing as below:

ZVRA's Degree of Financial Leverage is ranked better than
62.25% of 1441 companies
in the Biotechnology industry
Industry Median: 0.94 vs ZVRA: 0.73

Zevra Therapeutics Degree of Financial Leverage Historical Data

The historical data trend for Zevra Therapeutics's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zevra Therapeutics Degree of Financial Leverage Chart

Zevra Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.16 1.10 -0.40 -0.32 0.98

Zevra Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.98 0.74 0.82 0.73

Competitive Comparison of Zevra Therapeutics's Degree of Financial Leverage

For the Biotechnology subindustry, Zevra Therapeutics's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zevra Therapeutics's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Zevra Therapeutics's Degree of Financial Leverage falls into.



Zevra Therapeutics Degree of Financial Leverage Calculation

Zevra Therapeutics's Degree of Financial Leverage for the quarter that ended in Sep. 2024 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -2.11 (Sep. 2024) / -0.6 (Sep. 2023) - 1 )/( -83.751 (Sep. 2024) / -18.773 (Sep. 2023) - 1 )
=2.5167/3.4612
=0.73***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Zevra Therapeutics  (NAS:ZVRA) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Zevra Therapeutics Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Zevra Therapeutics Business Description

Traded in Other Exchanges
Address
1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Executives
Watton Corey Michael director 22045 KAREN STREET, ELKHORN NE 68022
R. Laduane Clifton officer: VP Fin & Corp Controller C/O KEMPHARM, INC., 1170 CELEBRATION BLVD., #103, CELEBRATION FL 34747
Thomas Anderson director 215 FIRST STREET, CAMBRIDGE MA 02142
John B Bode director C/O TRIBUNE PUBLISHING COMPANY, 202 W. FIRST STREET, LOS ANGELES CA 90012
Neil F. Mcfarlane director, officer: President and CEO C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Joshua Schafer officer: CCO & EVP, Bus. Development SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Douglas W Calder director 324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Wendy L Dixon director
Tamara A Seymour director C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Timothy J. Sangiovanni officer: VP, Corporate Controller C/O KEMPHARM, INC., 2500 CROSSPARK RD, STE E-126, CORALVILLE IA 52241
Matthew R Plooster director 2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241
David S Tierney director C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Richard W Pascoe director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Christopher Posner director C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Travis C Mickle director, 10 percent owner, officer: President & CEO 2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241